(Q33660289)

English

The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer (English)

1 reference

Europe PubMed Central

28 July 2017

1 reference

based on heuristic

inferred from title

author name string

A Hamilton

1

1 reference

Europe PubMed Central

28 July 2017

M Piccart

2

1 reference

Europe PubMed Central

28 July 2017

publication date

1 April 1999

1 reference

Europe PubMed Central

28 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

28 July 2017

10

1 reference

Europe PubMed Central

28 July 2017

377-384

1 reference

Europe PubMed Central

28 July 2017

4

1 reference

Europe PubMed Central

28 July 2017

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008368300827

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008368300827

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008368300827

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008368300827

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008368300827

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008368300827

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33660289&oldid=1966906127"